期刊文献+

血清铁蛋白对急性冠脉综合征介入术后造影剂引起肾病发生的预测研究 被引量:6

Diagnostic value of serum ferritin in contrast-induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome
下载PDF
导出
摘要 目的探讨血清铁蛋白(SF)对急性冠脉综合征(ACS)患者经皮冠脉介入术(PCI)后造影剂引起肾病(CIN)发生的影响。方法选取2015年1月—2017年6月承德市中心医院心内科行PCI治疗的ACS患者368例。据入院发病时血清铁蛋白水平以三分位数法分为3组(A组SF<160 ng/ml,B组SF 160 ng/ml~<258 ng/ml,C组SF≥258 ng/ml),比较不同组ACS患者PCI术后CIN发生率,分析其影响因素。结果 368例患者发生CIN 39例,发生率为10.6%;A组106例,发生CIN 9例,发生率为8.5%;B组153例,发生CIN 11例,发生率为7.2%;C组109例,发生CIN 19例,发生率为17.4%;3组间比较差异有统计学意义(P <0.05)。ROC曲线显示SF为239.5 ng/ml时预测CIN发生具有68.4%的敏感性和65.2%的特异性(曲线下面积为0.727,95%CI:0.663,0.790);多因素Logistic回归分析显示术前SF≥258 ng/ml,[O^R=2.677(95%CI:1.606,4.462),P=0.000]、血清肌酐升高[O^R=1.029(95%CI:1.001,1.058),P=0.046]、血清尿素升高[O^R=1.553(95%CI:1.145,2.107),P=0.005]是CIN发生的危险因素,射血分数升高[O^R=-0.054(95%CI:0.898,0.999),P=0.048]是CIN发生的保护因素。结论高水平SF、术前肾功能异常对ACS患者介入治疗后CIN具有预测作用,射血分数是CIN发生的保护因素。 Objective To study the diagnostic value of serum ferritin(SF)in contrast-induced nephropathy(CIN)after percutaneous coronary intervention(PCI)in patients with acute coronary syndrome(ACS).Methods Totally 368 hospitalized patients with acute coronary syndrome received percutaneous coronary intervention during January 2015 to June 2017.Patients were enrolled in this study and were divided into three groups according to levels of serum ferritin:A group(SF<160 ng/ml,n=106),B group(SF 160 ng/ml~<258 ng/ml,n=153),and C group(SF≥258 ng/ml,n=109).Incidence of CIN was recorded.Results CIN occurred in 39 of 368 patients(10.6%),of which 9 cases(8.5%)in group A,11 cases(7.2%)in group B,19 cases(17.4%)in group C.The incidence of contrastinduced nephropathy was statistically significant among three groups(P<0.05).ROC curve showed sensitivity and specificity of SF was 65.2%and 68.4%,respectively when SF was 239.5ng/ml.Multivariate Logistic regression analysis manifested that SF≥258 ng/ml,serum creatinine and serum urea were identified as risk factors for CIN.Ejection fraction was identified as protective factor for CIN[OR=-0.054,(95%CI:0.898,0.999),P=0.048].Conclusions High levels of serum ferritin and renal injury may increase the risk of contrast-induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome.
作者 王玉慧 陈建华 吕彦辉 董铁铸 罗东雷 郭靖涛 Yu-hui Wang;Jian-hua Chen;Yan-hui Lü;Tie-zhu Dong;Dong-lei Luo;Jing-tao Guo(Department of Nephrology,Chengde Central Hospital,Chengde,Hebei 067000,China;Department of Cardiology,Chengde Central Hospital,Chengde,Hebei 067000,China)
出处 《中国现代医学杂志》 CAS 2019年第7期80-85,共6页 China Journal of Modern Medicine
基金 河北省2018年度医学科学研究重点课题(No:20181168)
关键词 造影剂引起肾病/肾疾病 急性冠脉综合征 血清铁蛋白 contrast agent-induced nephropathy/kidney diease acute coronary syndrome serum ferritin
  • 相关文献

参考文献8

二级参考文献93

  • 1李建薇,田浩明.铁超负荷与糖尿病[J].国外医学(内科学分册),2004,31(10):442-444. 被引量:11
  • 2王秀问,张宝珠,段明英.高铁蛋白血症与糖尿病肾病的关系[J].山东医药,1996,36(12):5-6. 被引量:3
  • 3柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2125
  • 4Kang ES,Kim HJ,Ahn CW,et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes[ J ]. Diabetes Res Clin Pratt,2005, 69(2): 151.
  • 5Barzilay JI,Abraham L,Heckbert SR,el al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study[J]. Diahetes,2001,50( 10):2384.
  • 6Stehouwer CDA, Gall MA, Twisk JW, et al. Increased urinaryalbumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death [ J ]. Diabetes,2006,51 : 1157.
  • 7AbrahamianH,EndlerG, ExnerM, etal. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of pminflamnmtory cytokines[J]. Exp Clin Endocrinol Diabetes,2007,115(1):38.
  • 8Devara JS,Xu DY. C-reactive protein increases plasmin ogen activator in hibitor-lexpression and activity in human aorticendothelial cells: implications for the metabolic syndrome and atherohrembosis [ J ]. Circulation, 2003,107: 398 - 404.
  • 9Curler P. Defemxamine therapy in high-ferritin diabetes [ J ]. Diabetes,2003,38(9) : 1207.
  • 10You SA, Wang Q. Ferritin in atherosclerosis [J]. Clin Chim Acta, 2005,357:1-5.

共引文献53

同被引文献69

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部